Global

Welcome to Pharm Exec's new guest column on navigating the geopolitical risks challenging core company strategies in today's shifting global landscape for healthcare.

Recent policy shifts in these two influential health technology assessment markets signal a broader regional move toward faster, more innovation-friendly access frameworks.

The stock increased after positive Q3 earnings and deals with the Trump administration.

The Swiss region hopes to attract pharma companies looking to escape uncertainty in the US market.

Eli Lilly invests $3 billion in a new European manufacturing facility, enhancing production capacity and creating jobs while ensuring faster access to innovative medicines.

Eli Lilly invests $1.2 billion in Puerto Rico to enhance manufacturing capabilities, creating jobs and integrating advanced technologies for oral medicines.

President Trump’s latest attempt at implementing International Reference Pricing- based (IRP-) methodology to regulate drug prices in the US has the broadest and strictest scope.

Ypsomed invests $250 million in a new U.S. manufacturing facility, enhancing local supply and creating jobs in Holly Springs, North Carolina.

The company announced the plans as President visited the UK.

Challenging six misconceptions that have characterized product strategies in Central and Eastern European markets.

Sources say the President’s focus has shifted.

The 15% tariff on pharmaceutical imports from the European Union is not a short term inconvenience, it represents a structural shift in the economics of the US pharmaceutical market.

The letter states that the companies have 60 days to meet the President's requirements.

Jeff Liter, CEO of Luminary, discusses his company’s approach to CAR-T therapies and why the developing Saudi market has potential.

During a high-level US visit, the Department of Health—Abu Dhabi signed strategic agreements with Abbott, Boehringer Ingelheim, and Sanofi to boost pharmaceutical manufacturing, expand vaccine development, and advance digital health and clinical research.

A look at China's emergence as a hub for novel treatment pursuits—and ways international investors can best capitalize on the favorable research trajectory.

The GMRLN plays an important role in identifying outbreaks early and providing the necessary support to control them.

In this Pharmaceutical Executive exclusive, Bob Jansen, David Shulkin, Gen. Paul Funk (Ret.), and Maj. Gen. Dennis LeMaster (Ret.)—members of the Federated Healthcare Advisory Panel—discuss how pharmaceutical companies can strengthen supply chain resilience, navigate policy shifts, and adopt a national security mindset.

Country is poised to offer growth-channel opportunities for global pharma companies ready to scale access, innovation, and profitability.

The Regeneron SVP details the company’s approach to reaching oncology patients across the planet.

The chaotic tariff situation is forcing pharma companies to prepare for multiple outcomes.

While supply chain interruptions are a strong possibility, the tariffs also provide the industry with a chance to improve certain conditions.

Four tips for midsized companies when entering new global markets.

The pharmaceutical company had previously been subjected to a 2-year suspension.

Pharma companies face unique challenges with market access in this region.